リン-32微球:肝細胞癌治療と抗PD1免疫療法の強化のための二重モードのトランス動脈放射性エンボリゼーションアプローチ
Shipeng Dai1, Xunzheng Su2, Zhuozheng Li3
1Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Materials today. Bio
|September 2, 2025
まとめ
新しいリン-32微球 (32P-MS) は肝細胞癌 (HCC) の治療に有望である. この新型トランス動脈放射線栓塞療法 (TARE) は,腫瘍を効果的に縮小し,抗PD1免疫療法の反応を強化します.
科学分野:
- 腫瘍学
- 放射線科
- 免疫学
背景:
- トランス動脈放射線栓塞 (TARE) は肝細胞癌 (HCC) の治療に不可欠です.
- 現在の90Yマイクロスフィアは,複雑さ,半減期,高コストなどの制限があります.
- HCCの治療を改善するために,新しい放射性核素微球が必要である.
研究 の 目的:
- HCCの治療のために,リン-32負荷の微球 (32P-MS) を開発し,評価する.
- 32P-MS TAREの in vitroおよびin vivoの有効性を調査する.
- HCCにおける32P-MSの免疫調節メカニズムを解明する.
主な方法:
- In vitro検査では,HCC細胞の増殖,移動,侵入,アポトーシスを評価した.
- In vivo試験では,PET-CT,HE,TUNEL,Ki67分析によるHCCモデルで32P-MS TAREを使用した.
- RNAシーケンシング,質量サイトメトリー,分子ドッキング,コローカライゼーション,Co-IPアッセイは分子経路を調査した.
主要な成果:
- P- MSはHCC細胞の増殖を抑制し,インビトロでアポトーシスを誘発した.
- 腫瘍の体積と体重は,全身性毒性なしに減少した.
- FABP1/PPARG/PD-L1軸経由でFABP1+PD-L1+ミエロイド系抑制細胞 (MDSCs) を増調し,免疫抑制に寄与した.
- FABP1を阻害したり,PD1抑制剤を併用したりすることで,抗腫瘍効果とT細胞活性が強化された.
結論:
- P-MSは,直接的な抗腫瘍効果を持つ強力なHCC治療薬である.
- P- MSは,MDSCとPD- L1経路を標的として免疫調節機能を発揮する.
- 32P- MS TAREと免疫チェックポイント阻害剤を併用すると,HCCの免疫抑制に相乗効果がある.
関連する概念動画
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


